Diacerein - TWi Biotechnology

Drug Profile

Diacerein - TWi Biotechnology

Alternative Names: AC-201; AC-201 Controlled release tablet; AC-201CR; AC-203; CCP 020

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TWi Biotechnology; TWi Pharmaceuticals
  • Developer Castle Creek Pharmaceuticals; TWi Biotechnology
  • Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action Caspase 1 inhibitors; Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Epidermolysis bullosa
  • Phase II Bullous pemphigoid; Gout; Joint disorders; Type 2 diabetes mellitus
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 09 Aug 2018 Diacerein - TWi Biotechnology receives Fast Track designation for Epidermolysis bullosa [Topical,Ointment] (In adolescents, In children, In the elderly, In adults) in USA
  • 16 May 2018 Diacerein receives Rare paediatric disease designation for Epidermolysis bullosa in USA
  • 16 May 2018 Diacerein receives rare paediatric disease designation for Epidermolysis bullosa in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top